Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CR Pharm Files for $368.5 Million China Pharma Fund

publication date: Oct 25, 2017

China Resources Pharmaceutical filed with the Hong Kong exchange to raise $368.5 million in an investment fund. The fund will be run by its subsidiary, CR Pharm (Shantou). It will make equity investments in China pharma companies, though it was not disclosed whether the fund's character will be venture or private equity. CR Pharm, China's second-largest drugmaker, staged a $1.8 billion IPO in Hong Kong last year. Three of its subsidiaries are listed companies in China.

Stock Symbol: (HK: 3320)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.